{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T21:25:54Z","timestamp":1780953954308,"version":"3.54.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T00:00:00Z","timestamp":1619740800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T00:00:00Z","timestamp":1619740800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Self-sampling for human papillomavirus (HPV) testing is a feasible option to improve the cervical screening coverage. However, an ideal triage method for HPV-positive self-samples does not yet exist. The aim of this study was to explore the utility of HPV genotyping and p16<jats:sup>INK4a<\/jats:sup> immunostaining (p16) in triaging HPV-positive self-samples, focusing on HPV-positive, cytology-negative (HPCN) women.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A total of 73,699 women were screened in a cervical screening project in China via SeqHPV assay on self-samples. HPV-positive women were called-back and collected cervical sample for p16 immunostaining and liquid-based cytology, those who met any result of HPV16\/18+ or visual inspection with acetic acid (VIA)\u2009+\u2009or p16+ were referred for colposcopy, and HPCN women with adequate data on p16 and pathology were analyzed. A triage strategy was considered acceptable if the negative predictive value (NPV) for cervical intraepithelial neoplasia 3 or worse (CIN3+) was 98% or more, combined with an improvement of sensitivity and specificity for CIN2+\/CIN3+ in reference to the comparator, being HPV16\/18\u2009+\u2009.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 2731 HPCN women aged 30\u201364\u2009years were enrolled, 136 (5.0%) CIN2+ and 53 (1.9%) CIN3+ were detected. Five triage strategies met the criteria: p16+; HPV16\/33+; \u2018HPV16+ or HPV33\/58\/31\/35+&amp;p16+\u2019; \u2018HPV16\/33+ or HPV58\/31\/35+&amp;p16+\u2019; HPV16\/18\/31\/33\/45\/52\/58\u2009+\u2009&amp; p16+. These strategies required less or similar colposcopy referrals, and less colposcopies to detected one case of CIN2+\/CIN3+, achieving favorable false positive (negative) rates to the comparator. Among them, p16 staining detected 83.1% (79.2%) of underlying CIN2\u2009+\u2009(CIN3+) in HPCN women. Moreover, three triage strategies were favorable in sensitivity and\/or specificity to the \u2018HPV16\/33+\u2019 strategy: p16+; \u2018HPV16+ or HPV33\/58\/31\/35\u2009+\u2009&amp;p16+\u2019; HPV16\/18\/31\/33\/45\/52\/58\u2009+\u2009&amp;p16\u2009+\u2009.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Genotyping for HPV16\/33 could be utilized to optimize the management of HPCN women. Moreover, p16 immunostaining, either alone or combined with extended genotypes, is more effective than HPV genotypes alone in the triage of HPCN women.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-021-06109-4","type":"journal-article","created":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T10:03:24Z","timestamp":1619777004000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Triaging HPV-positive, cytology-negative cervical cancer screening results with extended HPV genotyping and p16INK4a immunostaining in China"],"prefix":"10.1186","volume":"21","author":[{"given":"Fangbin","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peisha","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinfeng","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruifang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,30]]},"reference":[{"issue":"11","key":"6109_CR1","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","volume":"11","author":"S Sd","year":"2010","unstructured":"Sd S, Quint WGV, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1048\u201356.","journal-title":"Lancet Oncol"},{"issue":"7","key":"6109_CR2","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1001\/jama.2018.10400","volume":"320","author":"J Melnikow","year":"2018","unstructured":"Melnikow J, Henderson JT, Burda BU, Senger CA, Durbin S, Weyrich MS. Screening for cervical Cancer with high-risk human papillomavirus testing: updated evidence report and systematic review for the US preventive services task force. JAMA. 2018;320(7):687\u2013705. https:\/\/doi.org\/10.1001\/jama.2018.10400.","journal-title":"JAMA"},{"issue":"9","key":"6109_CR3","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/S1470-2045(11)70188-7","volume":"12","author":"PE Castle","year":"2011","unstructured":"Castle PE, Stoler MH, Wright TC Jr, Sharma A, Wright TL, Behrens CM. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol. 2011;12(9):880\u201390. https:\/\/doi.org\/10.1016\/S1470-2045(11)70188-7.","journal-title":"Lancet Oncol"},{"issue":"10","key":"6109_CR4","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1002\/cncy.22180","volume":"127","author":"X Tao","year":"2019","unstructured":"Tao X, Zhang H, Li J, Zhang H, Xiao J, Zhang L, et al. Prevalence of HPV-16\/18 genotypes and immediate histopathologic correlation results in a Chinese population with negative cytology and positive high-risk HPV testing. Cancer Cytopathol. 2019;127(10):650\u20137. https:\/\/doi.org\/10.1002\/cncy.22180.","journal-title":"Cancer Cytopathol"},{"issue":"3","key":"6109_CR5","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3322\/caac.21139","volume":"62","author":"D Saslow","year":"2012","unstructured":"Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012;62(3):147\u201372. https:\/\/doi.org\/10.3322\/caac.21139.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"6109_CR6","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1128\/JCM.02116-14","volume":"53","author":"M Schiffman","year":"2015","unstructured":"Schiffman M, Burk RD, Boyle S, Raine-Bennett T, Katki HA, Gage JC, et al. A study of genotyping for Management of Human Papillomavirus-Positive, cytology-negative cervical screening results. J Clin Microbiol. 2015;53(1):52\u20139. https:\/\/doi.org\/10.1128\/JCM.02116-14.","journal-title":"J Clin Microbiol"},{"issue":"6","key":"6109_CR7","doi-asserted-by":"publisher","first-page":"e0234518","DOI":"10.1371\/journal.pone.0234518","volume":"15","author":"F Song","year":"2020","unstructured":"Song F, Du H, Wang C, Huang X, Wu R. The effectiveness of HPV16 and HPV18 genotyping and cytology with different thresholds for the triage of human papillomavirus-based screening on self-collected samples. PLoS One. 2020;15(6):e0234518. https:\/\/doi.org\/10.1371\/journal.pone.0234518.","journal-title":"PLoS One"},{"issue":"20","key":"6109_CR8","doi-asserted-by":"publisher","first-page":"6157","DOI":"10.7150\/jca.48357","volume":"11","author":"F Song","year":"2020","unstructured":"Song F, Du H, Xiao A, Wang C, Huang X, Liu Z, et al. Type-specific distribution of cervical hrHPV infection and the association with cytological and histological results in a large population-based cervical Cancer screening program: baseline and 3-year longitudinal data. J Cancer. 2020;11(20):6157\u201367. https:\/\/doi.org\/10.7150\/jca.48357.","journal-title":"J Cancer"},{"issue":"10","key":"6109_CR9","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1002\/ijc.33035","volume":"147","author":"T Malagon","year":"2020","unstructured":"Malagon T, Volesky KD, Bouten S, Laprise C, El-Zein M, Franco EL. Cumulative risk of cervical intraepithelial neoplasia for women with normal cytology but positive for human papillomavirus: systematic review and meta-analysis. Int J Cancer. 2020;147(10):2695\u2013707. https:\/\/doi.org\/10.1002\/ijc.33035.","journal-title":"Int J Cancer"},{"issue":"3","key":"6109_CR10","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1002\/ijc.28605","volume":"135","author":"CM Wheeler","year":"2014","unstructured":"Wheeler CM, Hunt WC, Cuzick J, Langsfeld E, Robertson M, Castle PE, et al. The influence of type-specific human papillomavirus infections on the detection of cervical precancer and cancer: a population-based study of opportunistic cervical screening in the United States. Int J Cancer. 2014;135(3):624\u201334. https:\/\/doi.org\/10.1002\/ijc.28605.","journal-title":"Int J Cancer"},{"issue":"Suppl 1","key":"6109_CR11","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1016\/j.jcv.2015.11.015","volume":"76","author":"N Wentzensen","year":"2016","unstructured":"Wentzensen N, Schiffman M, Palmer T, Arbyn M. Triage of HPV positive women in cervical cancer screening. J Clin Virol. 2016;76(Suppl 1):S49\u201355. https:\/\/doi.org\/10.1016\/j.jcv.2015.11.015.","journal-title":"J Clin Virol"},{"issue":"2","key":"6109_CR12","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1097\/LGT.0000000000000531","volume":"24","author":"M Schiffman","year":"2020","unstructured":"Schiffman M, Wentzensen N, Perkins R, Guido R. An introduction to the 2019 ASCCP risk-based management consensus guidelines. J Low Genit Tract Dis. 2020;24(2):87\u20139. https:\/\/doi.org\/10.1097\/LGT.0000000000000531.","journal-title":"J Low Genit Tract Dis"},{"issue":"3","key":"6109_CR13","doi-asserted-by":"publisher","first-page":"e58678","DOI":"10.1371\/journal.pone.0058678","volume":"8","author":"JS Song","year":"2013","unstructured":"Song JS, Kim EJ, Choi J, Gong G, Sung CO. Significance of HPV-58 infection in women who are HPV-positive, cytology-negative and living in a country with a high prevalence of HPV-58 infection. PLoS One. 2013;8(3):e58678. https:\/\/doi.org\/10.1371\/journal.pone.0058678.","journal-title":"PLoS One"},{"issue":"3","key":"6109_CR14","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1002\/ijc.26404","volume":"131","author":"PK Chan","year":"2012","unstructured":"Chan PK, Cheung TH, Li WH, Yu MY, Chan MY, Yim SF, et al. Attribution of human papillomavirus types to cervical intraepithelial neoplasia and invasive cancers in southern China. Int J Cancer. 2012;131(3):692\u2013705. https:\/\/doi.org\/10.1002\/ijc.26404.","journal-title":"Int J Cancer"},{"issue":"1","key":"6109_CR15","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ygyno.2018.12.024","volume":"153","author":"MH Stoler","year":"2019","unstructured":"Stoler MH, TCW J, Parvu V, Yanson K, Cooper CK, Andrew J. Stratified risk of high-grade cervical disease using onclarity HPV extended genotyping in women, >\/=25 years of age, with NILM cytology. Gynecol Oncol. 2019;153(1):26\u201333. https:\/\/doi.org\/10.1016\/j.ygyno.2018.12.024.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"6109_CR16","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1186\/s12885-020-06935-w","volume":"20","author":"J Zhang","year":"2020","unstructured":"Zhang J, Zhang D, Yang Z, Wang X, Wang D. The role of human papillomavirus genotyping for detecting high-grade intraepithelial neoplasia or cancer in HPV-positive women with normal cytology: a study from a hospital in northeastern China. BMC Cancer. 2020;20(1):443. https:\/\/doi.org\/10.1186\/s12885-020-06935-w.","journal-title":"BMC Cancer"},{"issue":"3","key":"6109_CR17","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1002\/cncy.20078","volume":"118","author":"P Samarawardana","year":"2010","unstructured":"Samarawardana P, Dehn DL, Singh M, Franquemont D, Thompson C, Gaido L, et al. p16(INK4a) is superior to high-risk human papillomavirus testing in cervical cytology for the prediction of underlying high-grade dysplasia. Cancer Cytopathol. 2010;118(3):146\u201356. https:\/\/doi.org\/10.1002\/cncy.20078.","journal-title":"Cancer Cytopathol"},{"issue":"2","key":"6109_CR18","first-page":"1","volume":"28","author":"MZ Wu","year":"2018","unstructured":"Wu MZ, Wang S, Zheng M, Tian LX, Wu X, Guo KJ, et al. The diagnostic utility of p16 Immunostaining in differentiating Cancer and HSIL from LSIL and benign in cervical cells. Cell Transplant. 2018;28(2):1\u20136.","journal-title":"Cell Transplant"},{"issue":"2","key":"6109_CR19","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S1470-2045(18)30763-0","volume":"20","author":"JP Nicole","year":"2019","unstructured":"Nicole JP, Ebisch RMF, Heideman D a M, Melchers WJG, Bekkers RLM, Molijn AC, et al. Performance of human papillomavirus testing on self-collected versus clinician-collected samples for the detection of cervical intraepithelial neoplasia of grade 2 or worse: a randomised, paired screen-positive, non-inferiority trial. Lancet Oncol. 2019;20(2):229\u201338.","journal-title":"Lancet Oncol"},{"issue":"3","key":"6109_CR20","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.ygyno.2014.01.006","volume":"132","author":"JL Belinson","year":"2014","unstructured":"Belinson JL, Wang G, Qu X, Du H, Shen J, Xu J, et al. The development and evaluation of a community based model for cervical cancer screening based on self-sampling. Gynecol Oncol. 2014;132(3):636\u201342. https:\/\/doi.org\/10.1016\/j.ygyno.2014.01.006.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"6109_CR21","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/LGT.0000000000000577","volume":"25","author":"H Du","year":"2021","unstructured":"Du H, Duan X, Liu Y, Shi B, Zhang W, Wang C, et al. Evaluation of Cobas HPV and SeqHPV assays in the Chinese multicenter screening trial. J Low Genit Tract Dis. 2021;25(1):22\u20136. https:\/\/doi.org\/10.1097\/LGT.0000000000000577.","journal-title":"J Low Genit Tract Dis"},{"issue":"6","key":"6109_CR22","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1309\/AJCP9P2KJSXEKCJB","volume":"141","author":"X Yi","year":"2014","unstructured":"Yi X, Zou J, Xu J, Liu T, Liu T, Hua S, et al. Development and validation of a new HPV genotyping assay based on next-generation sequencing. Am J Clin Pathol. 2014;141(6):796\u2013804. https:\/\/doi.org\/10.1309\/AJCP9P2KJSXEKCJB.","journal-title":"Am J Clin Pathol"},{"key":"6109_CR23","doi-asserted-by":"publisher","first-page":"9067","DOI":"10.2147\/CMAR.S273079","volume":"12","author":"F Song","year":"2020","unstructured":"Song F, Du H, Xiao A, Wang C, Huang X, Yan P, et al. Evaluating the performance of p16INK4a immunocytochemistry in cervical Cancer screening. Cancer Manag Res. 2020;12:9067\u201375. https:\/\/doi.org\/10.2147\/CMAR.S273079.","journal-title":"Cancer Manag Res"},{"issue":"2","key":"6109_CR24","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1159\/000381842","volume":"59","author":"R Nayar","year":"2015","unstructured":"Nayar R, Wilbur DC. The Pap Test and Bethesda 2014. \"the reports of my demise have been greatly exaggerated.\" (after a quotation from mark twain). Acta Cytol. 2015;59(2):121\u201332.","journal-title":"Acta Cytol"},{"issue":"4","key":"6109_CR25","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1097\/LGT.0000000000000239","volume":"20","author":"JL Belinson","year":"2016","unstructured":"Belinson JL, Pretorius RG. A standard protocol for the colposcopy exam. J Low Genit Tract Dis. 2016;20(4):e61\u20132. https:\/\/doi.org\/10.1097\/LGT.0000000000000239.","journal-title":"J Low Genit Tract Dis"},{"issue":"1","key":"6109_CR26","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13027-020-00291-x","volume":"15","author":"Z Wang","year":"2020","unstructured":"Wang Z, Liu T, Wang Y, Gu Y, Wang H, Liu J, et al. Risk of cervical lesions in high-risk HPV positive women with normal cytology: a retrospective single-center study in China. Infect Agents Cancer. 2020;15(1):34. https:\/\/doi.org\/10.1186\/s13027-020-00291-x.","journal-title":"Infect Agents Cancer"},{"issue":"3","key":"6109_CR27","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1136\/sextrans-2019-054290","volume":"96","author":"RH Dodd","year":"2020","unstructured":"Dodd RH, Mac O, Brotherton JML, Cvejic E, McCaffery KJ. Levels of anxiety and distress following receipt of positive screening tests in Australia's HPV-based cervical screening programme: a cross-sectional survey. Sex Transm Infect. 2020;96(3):166\u201372. https:\/\/doi.org\/10.1136\/sextrans-2019-054290.","journal-title":"Sex Transm Infect"},{"issue":"11","key":"6109_CR28","doi-asserted-by":"publisher","first-page":"e1915781","DOI":"10.1001\/jamanetworkopen.2019.15781","volume":"2","author":"L Torres-Ibarra","year":"2019","unstructured":"Torres-Ibarra L, Cuzick J, Lorincz AT, Spiegelman D, Lazcano-Ponce E, Franco EL, et al. Comparison of HPV-16 and HPV-18 genotyping and cytological testing as triage testing within human papillomavirus-based screening in Mexico. JAMA Netw Open. 2019;2(11):e1915781. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.15781.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"6109_CR29","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/s12885-019-5583-7","volume":"19","author":"J Gago","year":"2019","unstructured":"Gago J, Paolino M, Arrossi S. Factors associated with low adherence to cervical cancer follow-up retest among HPV+\/cytology negative women: a study in programmatic context in a low-income population in Argentina. BMC Cancer. 2019;19(1):367. https:\/\/doi.org\/10.1186\/s12885-019-5583-7.","journal-title":"BMC Cancer"},{"issue":"6","key":"6109_CR30","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1158\/1940-6207.CAPR-14-0409","volume":"8","author":"MH U, NJ P, FJ VK, S VDH, BI W, D R, J B, PJ S, CJ M","year":"2015","unstructured":"MH U, NJ P, FJ VK, S VDH, BI W, D R, J B, PJ S, CJ M. Five-year cervical (pre) Cancer risk of women screened by HPV and cytology testing. Cancer Prev Res. 2015;8(6):502\u20138.","journal-title":"Cancer Prev Res"},{"issue":"7","key":"6109_CR31","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1001\/jamainternmed.2019.0306","volume":"179","author":"N Wentzensen","year":"2019","unstructured":"Wentzensen N, Clarke MA, Bremer R, Poitras N, Tokugawa D, Goldhoff PE, et al. Clinical evaluation of human papillomavirus screening with p16\/Ki-67 dual stain triage in a large organized cervical Cancer screening program. JAMA Intern Med. 2019;179(7):E1\u20138.","journal-title":"JAMA Intern Med"},{"issue":"1","key":"6109_CR32","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ygyno.2016.10.031","volume":"144","author":"TC Wright Jr","year":"2017","unstructured":"Wright TC Jr, Behrens CM, Ranger-Moore J, Rehm S, Sharma A, Stoler MH, et al. Triaging HPV-positive women with p16\/Ki-67 dual-stained cytology: results from a sub-study nested into the ATHENA trial. Gynecol Oncol. 2017;144(1):51\u20136. https:\/\/doi.org\/10.1016\/j.ygyno.2016.10.031.","journal-title":"Gynecol Oncol"},{"issue":"9","key":"6109_CR33","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1002\/ijc.32669","volume":"146","author":"MH Stoler","year":"2019","unstructured":"Stoler MH, Baker E, Boyle S, Aslam S, Ridder R, Huh WK, et al. Approaches to triage optimization in HPV primary screening: extended genotyping and p16\/Ki-67 dual-stained cytology - retrospective insights from ATHENA. Int J Cancer. 2019;146(9):2599\u2013607. https:\/\/doi.org\/10.1002\/ijc.32669.","journal-title":"Int J Cancer"},{"issue":"11","key":"6109_CR34","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1158\/1055-9965.EPI-19-0239","volume":"28","author":"R Adcock","year":"2019","unstructured":"Adcock R, Cuzick J, Hunt WC, McDonald RM, Wheeler CM. Role of HPV genotype, multiple infections and viral load on the risk of high-grade cervical neoplasia. Cancer Epidemiol Biomark Prev. 2019;28(11):1816\u201324. https:\/\/doi.org\/10.1158\/1055-9965.EPI-19-0239.","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"10","key":"6109_CR35","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1002\/ijc.29290","volume":"136","author":"MH Uijterwaal","year":"2014","unstructured":"Uijterwaal MH, Polman NJ, Witte BI, van Kemenade FJ, Rijkaart D, Berkhof J, et al. Triaging HPV-positive women with normal cytology by p16\/Ki-67 dual-stained cytology testing: baseline and longitudinal data. Int J Cancer. 2014;136(10):2361\u20138. https:\/\/doi.org\/10.1002\/ijc.29290.","journal-title":"Int J Cancer"},{"issue":"2","key":"6109_CR36","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/S1470-2045(12)70529-6","volume":"14","author":"F Carozzi","year":"2013","unstructured":"Carozzi F, Gillio-Tos A, Confortini M, Del Mistro A, Sani C, De Marco L, et al. Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial. Lancet Oncol. 2013;14(2):168\u201376. https:\/\/doi.org\/10.1016\/S1470-2045(12)70529-6.","journal-title":"Lancet Oncol"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06109-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-021-06109-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06109-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T10:05:23Z","timestamp":1619777123000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-021-06109-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,30]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["6109"],"URL":"https:\/\/doi.org\/10.1186\/s12879-021-06109-4","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,30]]},"assertion":[{"value":"10 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol and the digital informed consent was approved by the Ethics Committee from Peking University Shenzhen Hospital (No.2018035). All methods were carried out in accordance with the rules of the Declaration of Helsinki. The informed consent was obtained from every participant.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"400"}}